IMPACT BIOMEDICAL INC. IBO
Last close
3.60
2026-10-23
Market cap
$388.2M
2026-06-30 share count
52-week range
0.37 - 7.70
Valuation FY2025 figures against the last close
P/S12,129.9x
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-0.38
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $32.0K | — | — | $50.0K | — |
| Cost of revenue | $424.0K | — | — | — | — |
| Gross profit | -$392.0K | — | — | — | — |
| R&D | $340.0K | $278.0K | $1.7M | $1.2M | — |
| SG&A | $873.0K | $718.0K | $315.0K | $325.0K | — |
| Total operating expenses | — | $28.8M | $4.0M | $3.5M | — |
| Operating income | -$4.3M | -$28.8M | -$4.0M | -$3.4M | — |
| Interest expense | $793.0K | $1.1M | $444.0K | $462.0K | — |
| Pre-tax income | -$14.4M | -$24.7M | -$4.4M | -$7.9M | — |
| Income tax | $2.6M | $33.0K | — | $621.0K | — |
| Net income | -$11.8M | -$24.7M | -$4.3M | -$7.3M | — |
| EPS, basic | -0.38 | -2.30 | -0.07 | -0.10 | — |
| EPS, diluted | -0.38 | -2.30 | -0.07 | -0.10 | — |
| Shares, diluted (wtd. avg.) | 31.6M | 10.8M | 60.2M | 70.5M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cash and equivalents | $3.0K | $2.0M | $1.0K | $2.0K | — |
| Receivables | $5.0K | — | — | — | — |
| Inventory | $63.0K | — | — | — | — |
| Total current assets | $411.0K | $2.4M | $332.0K | $122.0K | — |
| Property, plant and equipment | — | $17.0K | $287.0K | $276.0K | — |
| Goodwill | — | — | $46.4M | $25.1M | — |
| Other intangibles | $17.0M | $17.8M | $18.9M | $20.0M | — |
| Total assets | $17.4M | $20.3M | $44.6M | $46.5M | — |
| Accounts payable | $347.0K | $314.0K | $832.0K | $539.0K | — |
| Short-term debt | — | — | $11.9M | — | — |
| Total current liabilities | $1.2M | $9.8M | $13.1M | $10.6M | — |
| Total liabilities | $1.9M | $13.1M | $16.4M | $13.8M | — |
| Retained earnings | -$49.5M | -$37.7M | -$13.0M | -$8.6M | — |
| Total equity | $12.6M | $4.3M | $28.3M | $32.7M | $39.9M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$1.9M | -$2.9M | -$2.9M | -$2.2M | — |
| Depreciation and amortisation | $1.1M | $1.1M | $1.1M | $1.1M | — |
| Stock-based compensation | $13.0K | $19.0K | — | — | — |
| Investing cash flow | $3.0K | $2.0K | -$15.0K | -$349.0K | — |
| Financing cash flow | -$109.0K | $4.8M | $2.9M | $2.5M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-009711.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | — | $50.0K | — | — | $32.0K |
| Gross profit | — | — | — | — | -$392.0K |
| Net income | — | -$7.3M | -$4.3M | -$24.7M | -$11.8M |
Recent filings and events
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Material agreement signed Item 1.01
- Material agreement signed Item 1.01
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Material agreement signed Item 1.01
- Annual report filed Form 10-K
- Material agreement signed Item 1.01
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Regulation FD disclosure Item 7.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |